This study is designed for individuals with moderately to severely active ulcerative colitis. It aims to assess a new treatment’s impact on symptoms and overall disease progression.
Eligibility:
• Diagnosed with ulcerative colitis for at least 90 days
• Diagnosis confirmed by recent endoscopy and biopsy